The Latvian market for hormones in dosage, excluding contraceptives and antibiotics, experienced fluctuations from 2013 to 2023. In 2023, the market value per capita was $25.41. Recent years, particularly 2020 to 2023, show a slight increase followed by stabilization, with 2022 experiencing a notable decrease from 2021 but rebounding modestly in 2023. The five-year CAGR indicates a moderate upward trend, despite the dip in 2022. Overall, from 2016 to 2023, the market remains stable with mild growth.
Future trends to watch for include:
- Potential technological advancements in hormone delivery systems.
- Increasing awareness and diagnosis of hormone-related conditions.
- Regulatory changes impacting market dynamics.
- Economic factors influencing healthcare spending.
